Latest Content

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

Jessica Steen, OD, FAAO, DipABO, stated that each ADC can have distinct ophthalmic monitoring needs and management protocols.

Lab-grown retinal endothelial cells from iPSCs rebuild mouse retinal vessels and power blood-retina barrier chips, accelerating diabetic retinopathy research and therapy discovery.

A disconnect between the signs and symptoms of OSD can easily lead to misdiagnosis or undertreatment if clinicians rely solely on a slit lamp observation.

University of Waterloo unveils chairside 3D-printed contacts, delivering custom-fit lenses in 20 minutes—potentially cutting weeks of trial fittings for irregular corneas.

NEI-funded US trial compares HALT MAX lenses, 0.05% atropine, and combination therapy to slow childhood myopia and axial elongation.

Esen K. Akpek, MD, speaks with the Eye Care Network in recognition of Dry Eye Awareness Month.

A new pilot trial tests ZOC2017217 lanosterol-derived cataract eye drops, aiming to slow lens clouding and guide Phase 3 development amid mixed human evidence.

In this Q&A, LENZ CFO Dan Chevallard on Vizz's ECP momentum, telehealth expansion, and the global push to end reading glasses for presbyopia.

The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, stated that preparing optometric students for the possibility of burnout may help reduce its prevalence.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her AOA Optometry's Meeting 2026 session.

Alcon's TikTok, YouTube, and Instagram campaign uses creator-led patient stories to reintroduce LASIK to younger consumers and prompt conversations with surgeons.